Amarin
Corporation plc AMRN, a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that the United States Patent and Trademark Office
(USPTO) has published notification of Notice of Allowance for U.S. Patent
Application Serial Number 13/614,146. This application includes claims
intended to protect the Vascepa^® (icosapent ethyl) indication approved by the
U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical
trial results.
A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patent would have a term
that expires no earlier than in 2030. After issuance, Amarin plans to list
this patent in the FDA's Approved Drug Products with Therapeutic Equivalence
Evaluations, or Orange Book.
The claims in this allowed application cover a method of use relating to
Vascepa's MARINE indication. Specifically, the allowed independent claim
covers use of icosapent ethyl, or EPA, including Vascepa, in lowering
triglycerides through the daily administration of about 2500 mg to about 5000
mg of EPA, independent of DHA content, present in one or more capsules,
effective to lower triglycerides in the subject by at least 25% without
increasing LDL-C by more than 5%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in